ZEDI
LIVE

Serial Number

77837613

Owner

Zedira GmbH

Attorney

Dwayne K. Goetzel

Filing Date

Sep 29, 2009

Add to watchlist:

No watchlists yet
View on USPTO

ZEDI Trademark

Serial Number: 77837613 • Registration: 3927419

ZEDI is a trademark filed by Zedira GmbH on September 29, 2009. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Zedira GmbH (4 trademarks)

RoBlerstraBe 83
Darmstadt 64293 , DE

Entity Type: 03

Trademark Details

Filing Date

September 29, 2009

Registration Date

March 8, 2011

Published for Opposition

December 21, 2010

Goods & Services

[ (( Medicines for the treatment of celiac diseases, autoimmune diseases, food intolerances, intestinal diseases, irritable bowel syndrome, fibrosis, scarring, hypertrophic scars, scleroderma, diabetic nephropathy, hepatic fibrosis, cirrhosis, pulmonary fibrosis, atherosclerosis, cancer, thrombolytic therapy, acne, skin aging, psoriasis, neurodegenerative diseases, Alzheimer's disease, Huntington's diseases, Parkinson's disease, cataracts, affection by microorganisms, infections or candidiasis; pharmaceutical and veterinary medical products, namely, preparations for healthcare for the treatment of celiac diseases, autoimmune diseases, food intolerances, intestinal diseases, irritable bowel syndrome, fibrosis, scarring, hypertrophic scars, scleroderma, diabetic nephropathy, hepatic fibrosis, cirrhosis, pulmonary fibrosis, atherosclerosis, cancer, thrombolytic therapy, acne, skin aging, psoriasis, neurodegenerative diseases, Alzheimer's disease, Huntington's diseases, Parkinson's disease, cataracts, affection by microorganisms, infections or candidiasis; preparations or pharmaceuticals, namely, for the treatment and prophylaxis of celiac diseases, autoimmune diseases, food intolerances, intestinal diseases, irritable bowel syndrome, fibrosis, scarring, hypertrophic scars, scleroderma, diabetic nephropathy, hepatic fibrosis, cirrhosis, pulmonary fibrosis, atherosclerosis, cancer, thrombolytic therapy, acne, skin aging, psoriasis, neurodegenerative diseases, Alzheimer's disease, Huntington's disease, Parkinson's disease, cataracts, bacterial or yeast infection, infections, or candidiasis; chemical and biochemical products, namely, chemical preparations in the nature of chemical reagents and biochemical preparations for medical purposes; chemical and biochemical products, namely, chemical preparations in the nature of chemical reagents and biochemical preparations for healthcare; chemical and biochemical products, namely, chemical preparations in the nature of chemical reagents and biochemical preparations for human and veterinary medical use; dietetic products, namely, dietary supplements, dietetic foods adapted for medical use; dietetic products, namely, dietary supplements, dietetic foods adapted for healthcare; dietetic products, namely, dietary supplements, dietetic foods adapted for human and veterinary medical use; dietary supplements for medical purposes; disinfectants for medical instruments, for hygienic purposes, for sanitary purposes; preparations for destroying vermin; chemical and biochemical products for medical science for use in or on the human or animal body, namely, biochemical preparations and chemical reagents; diagnostic agent for medical purposes; X-ray contrast agent for medical purposes; germicidal detergents for medical purposes )) ]

Chemical and biochemical products, namely, chemicals, chemical preparations, biochemical preparations for industrial or scientific purposes

Commissioned research in the field of medical research, medical devices and biological research; conducting research and development work in the medical, pharmaceutical, pharmacological, biochemical and/or medicine technological area on behalf of third parties; commissioned execution of clinical trials and clinical studies in the field of medical and scientific research; commissioned assessment of scientific projects in the field of quality assessment and evaluation, commissioned evaluation of clinical trials and studies in the field of quality assessment and evaluation; services of a biochemical laboratory; services of an analytical laboratory in the field of medical, biological and chemical

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Jun 4, 2021 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Jun 3, 2021 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Jun 3, 2021 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 3, 2021 APRE
TEAS SECTION 8 & 9 RECEIVED
Feb 26, 2021 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Mar 8, 2020 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Jun 5, 2018 NAS8
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Jun 5, 2018 8.PR
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
May 31, 2018 EROP
POST REGISTRATION ACTION MAILED - SEC. 8
Apr 6, 2018 PRA8
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 6, 2018 APRE
SEC. 15 ACKNOWLEDGEMENT - E-MAILED
Jan 19, 2017 NA15
REGISTERED - SEC. 15 ACKNOWLEDGED
Jan 19, 2017 15AK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 19, 2017 APRE
TEAS SECTION 15 RECEIVED
Dec 15, 2016 E15R
TEAS SECTION 8 RECEIVED
Dec 15, 2016 ES8R
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Dec 15, 2016 EWAF
REGISTERED-PRINCIPAL REGISTER
Mar 8, 2011 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 21, 2010 NPUB
PUBLISHED FOR OPPOSITION
Dec 21, 2010 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 15, 2010 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 11, 2010 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 10, 2010 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 10, 2010 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 10, 2010 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 10, 2010 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Nov 8, 2010 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Nov 5, 2010 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 26, 2010 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 25, 2010 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 25, 2010 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 25, 2010 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 25, 2010 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 25, 2010 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 20, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 20, 2010 CRFA
ASSIGNED TO LIE
Oct 18, 2010 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 15, 2010 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 4, 2010 GNFN
FINAL REFUSAL E-MAILED
Aug 4, 2010 GNFR
FINAL REFUSAL WRITTEN
Aug 4, 2010 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 15, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 15, 2010 CRFA
ASSIGNED TO LIE
Jul 15, 2010 ALIE
FAX RECEIVED
Jun 30, 2010 FAXX
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 29, 2010 TCCA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 29, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 29, 2009 GNRN
NON-FINAL ACTION E-MAILED
Dec 29, 2009 GNRT
NON-FINAL ACTION WRITTEN
Dec 29, 2009 CNRT
ASSIGNED TO EXAMINER
Dec 26, 2009 DOCK
NOTICE OF DESIGN SEARCH CODE MAILED
Oct 9, 2009 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 8, 2009 NWOS
NEW APPLICATION ENTERED
Oct 2, 2009 NWAP